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Sohag Chest HospitalAbstract Background: Most people will develop an acute respiratory tract infection (RTI) every
year. RTIs are also the commonest acute problem dealt with in primary care – the ‘bread and but-
ter’ of daily practice. Management of acute RTIs in the past concentrated on advising prompt
antibiotic treatment of presumptive bacterial infections.
Objective: To study the prescription patterns of antibiotics in treating lower respiratory tract
infections at Sohag Chest Hospital.
Patients and methods: This study included 50 adult in-patients with lower respiratory tract infec-
tions admitted at Sohag Chest Hospital and 20 chest physicians working at the same hospital. The
study depended upon collecting data from a questionnaire directed to the chest physicians. The 50
patients were subjected to full medical history and examination, chest X-rays and antibiotics
received as regards the route of administration, duration of treatment and possible switch therapy.
Results: Forty percent of the physicians considered text books and thirty percent of the physi-
cians considered pharmaceutical companies as a main source of information about antibiotics.
Ninety-ﬁve percent of physicians used to prescribe AB empirically. Sixty percent of physicians con-
sidered their own experience as a reference for empirical AB prescription. Almost all of the physi-
cians considered the presence of co-morbid diseases during AB prescription. Eighty percent of
physicians considered the severity of infection as the most important factor affecting the route of
AB administration. The results also showed that forty-ﬁve percent of physicians considered quino-
lones as the most common AB prescribed for empirical therapy. Fifty percent of physicians consid-
ered the 4–7 day duration for empirical therapy. Sixty-ﬁve percent of physicians considered
improvement of general condition as the most important factor in determining the efﬁcacy ofrculosis.
144 M.M. Ahmed et al.AB prescribed. Forty percent of physicians considered 2–3 day duration was enough to assess the
efﬁcacy of AB prescribed. Fifty percent of physicians included in the study changed the AB group in
case the prescribed AB was ineffective. The study showed that a majority of physicians used to
make sure that the prescribed AB was the one actually given to the patient. Most of the physicians
used to ask the patient before prescribing the AB if he was sensitive to a certain AB. Seventy-ﬁve
percent of physicians used to ask the patient about AB history in the last 3 months. As regards ﬁfty
percent of physicians, their AB prescription decision might be sometimes affected by the patient.
Conclusions: AB prescription practices need to be well evaluated in order to formulate an accept-
able rationale aiming at improving the global situation of antibiotic use. Many points have to be
taken into consideration such as increasing awareness of physicians about different widely accepted
guidelines.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Antibiotics are of the oldest discovered drugs that combat
speciﬁc micro organisms like bacteria and fungi. Although
there are several classiﬁcation schemes for antibiotics, based
on bacterial spectrum (broad vs. narrow) or route of adminis-
tration (injectable vs. oral vs. topical), or type of activity
(bactericidal vs. bacteriostatic), the most useful is based on
the chemical structure. Antibiotics within a structural class will
generally show similar patterns of effectiveness, toxicity and
allergic potential [1].
Antibiotics are the most frequently prescribed drugs among
hospitalized patients and there are reported concerns about the
continuous indiscriminate and excessive use of antimicrobial
agents that promote the emergence of antibiotic-resistant
organisms [2].
The global spread of antimicrobial resistance has become a
pressing problem, with a focus on the ICU due to the
increasing administration of ineffective antimicrobial regimens
associated with greater morbidity and mortality [3].
Antibiotics are often thought to be the ﬁrst line treatment in
lower respiratory tract infections; however, these are not indi-
cated in viral infections. It is important to use an appropriate
antibiotic selection based on the infecting organism and to
ensure this therapy changes with the evolving nature of
these infections and the emerging resistance to conventional
therapies [4].
There are a number of acute and chronic infections that can
affect the lower respiratory tract. The two most common
infections are bronchitis and pneumonia [5].
Acute respiratory infections (ARIs) are common and cause
signiﬁcant morbidity and contribute signiﬁcantly to the overall
disease load on the community [6].
In addition to their important social impact, ARIs are
frequent causes of medical care and consumption of antibiotics
[7].
Patients and methods
This study included 50 adult in-patients with lower respiratory
tract infections admitted at Sohag Chest Hospital and 20 chest
physicians working at the same hospital.The study depended upon collecting data from:
First questionnaire
Directed to 20 chest physicians working at Sohag Chest
Hospital:
1. What is your medical education?hMB.,B.Ch hDiploma hMaster2. Years of experience:h< 5 years h6–10 years h11–15 yearsh16–20 years h21 years3. Do you frequently deal with patients with lower respira-
tory tract infections?hYes hNo4. If yesﬁ Number of patients with LRTIS/week?h1–5 h6–10 h >115. Most frequent LRTIS you deal with: (please number
them in a descending manner)hCOPD,
AIEhCAP hHAP hBronchiectasis hIPF,
AIEhOthers
(please
state)6. Main source of your information about antibiotics (ABs):hText
BookhInternet hPharmaceutical
companieshMedical
journalshLectures
1457. In case you prescribe Abs, this is usually:Prescription patterns of antibioticshEmpirical hAccording to culture and sensitivity8. If empiricalﬁ it’s according to what?hOwn
experiencehInternational
guidelineshNational
guidelineshLocal
guidelines9. Does the presence of co-morbid disease affect your AB
prescription?hYes hNo10. What is the most frequent co-morbid disease you see
with LRTIs? (Please number them in a descending order)hChronic lung
diseaseshDM hHypertensionhCardiac diseases hLiver
diseaseshRenal diseaseshAlcoholism hMalignancies hCerebrovascular
diseaseshOther (please state)11. Decision of AB selection is usually according to:(you can
choose more than one)hSite of infection hPresence of co-morbiditieshSeverity of infection hPrice of ABshEﬃcacy of Abs hAvailability of ABshAge of the patient hAB side eﬀects12. Route of AB administration is usually according to:hSeverity of infection hAvailability of ABshCost of AB hSite of care13. What is the most frequently prescribed AB for empirical
therapy for LRTIs?hBroad spectrum penicillin hAminoglycosideshAntipseudomonal penicillin
hMacrolideshMacrolideshCephalosporin hClindamycinhQuinolones hTetracyclineshCarbapenems h-Others (please
state)14. How long is the period of empirical therapy you give to
your patients with LRTIs?h1–3 days h7–10 daysh4–7 days h>10 days15. What is the most frequently modiﬁed AB based on
culture?hBroad spectrum penicillin hAminoglycosideshAntipseudomonal penicillin hMacrolideshCephalosporin hClindamycinhQuinolones hTetracyclineshCarbapenems hOthers (please state)16. What is the most frequently prescribed AB for CAP?hBroad spectrum penicillin hAminoglycosideshAntipseudomonal penicillin hMacrolideshCephalosporin hClindamycinhQuinolones hTetracyclineshCarbapenems hOthers (please state)17. What is the most frequently prescribed AB for HAP?hBroad spectrum penicillin hAminoglycosideshAntipseudomonal penicillin hMacrolideshCephalosporin hClindamycinhQuinolones hTetracyclineshCarbapenems hOthers (please state)18. What is the most frequently prescribed AB for COPD,
AIE?hBroad spectrum penicillin hAminoglycosideshAntipseudomonal penicillin hMacrolideshCephalosporin hClindamycinhQuinolones hTetracyclineshCarbapenems hOthers (please state)19. Decision of AB prescription is usually based on:
hA-Clinical condition.
hB-Lab (leucocytosis-CRP-Sputum for gram)
hC-Radiological data.
hA+B
hB+C
hA+C
hA+B+C
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assessment, the most important symptom is:hFever hAmount of sputum hDyspneahPurulence of sputum hOther (please state)21. If the decision of AB prescription is based on lab data,
the most important is:hLeucocytosis hCRP hESRhSputum gram stain hSputum C&S22. How do you usually judge the efﬁcacy of AB prescribed?
hImprovement of general condition
hDecrease of white blood count
hChange of sputum character (ﬂ volume & ﬂ purulence)
23. Duration after which you decide that the prescribed AB
is ineffective:h<2days h2-3daysh3-5days h>5days24. In case you judge that prescribed AB is ineffective you
usually:hChange AB group hChange AB dosehOrder C&S examination of sputum hRevise the diagnosis25. Do you usually make sure that the AB prescribed is that
the one actually given to the patient?hYes hNo26. Do you ask the patient about AB history in the last 3
months?Table 1 Sex distribution.
hYes hNoNumber Percent
Female 18 36.0
Male 32 64.0
Total 50 100.027. Does the patient sometimes inﬂuence your AB prescrip-
tion decision?hYes hNoTable 2 Age description.
Mean 56.78
Median 57.00
Std. Deviation 12.989
Minimum 2128. Do you ask the patient before prescribing the AB if he is
sensitive to certain AB?Maximum 80hYes hNoCOPD, AIE = ChronicObstructive PulmonaryDisease, Acute
Infective Exacerbation; CAP = Community Acquired
Pneumonia; HAP =Hospital Acquired Pneumonia; IPF,
AIE = Interstitial Pulmonary Fibrosis, Acute Infective
Exacerbation; LRTIs = Lower Respiratory Tract Infections [8].
The 50 patients were subjected to the following:
1. Full medical history and examination.
2. Chest ‘‘X’’ ray.
3. Antibiotics received:
 Antibiotics prescribed on admission.
 Route of AB administration.
 Duration of ABs given.
 If there is switch from parenteral to oral therapy.
 If there is change of ABs group or not.
 If yesﬁ which group? Duration and cause of such change.Statistical methodology
The statistics of this thesis was done using the IBM-SPSS
software (version 19) and Microsoft EXEL (version2013).
Quantitative data were expressed as mean ± SD, and
qualitative data were expressed as number and percentages.
As this study is descriptive, no analytical statistics were
needed.
Results
Patients
Table 1 shows that 32 patients (64%) were males, while 18
(36%) were females.
Table 2 shows that the age group of the patients included in
the study ranged from 21 years to 80 years, with a mean
56.78 years ±12.989 (see Fig. 1).
Table 3 shows that 15 patients (30%) were ex-smokers,
never smoking were 13 (26%), 9 (18%) were current cigarette
smokers, 9 (18%) were Shisha and Goza smokers and 4 (8%)
were passive smokers.
Seventy-six percent (76%) of the patients included in the
study had no history of taking antibiotics 3 months before
admission, while (24%) of patients had such history.
Table 4 shows that the most common clinical symptom in
the studied cases was cough and expectoration in 47 patients
Figure 1 Age description.
Table 3 Special habits.
Number Percent
Never smoking 13 26.0
Passive smoking 4 8.0
Ex-smoker 15 30.0
Current cigarette smoking 9 18.0
Shisha and Goza 9 18.0
Total 50 100.0
Table 4 Clinical manifestations.
Variable Yes No
No. Percent No. Percent
Fever 26 52 24 48
Cough/expectoration 47 94 3 6
Haemoptysis 10 20 40 80
Worsening of dyspnea 34 68 16 32
Co-morbid diseases 10 20 40 80
Increased temperature 24 48 26 52
High respiratory rate 26 52 24 48
Antibiotics in the last 3 months 12 24 38 76
Consolidation 12 24 38 76
Sonorous ronchi 40 80 10 20
Coarse crepitations 26 52 24 48
Table 5 Chest X-ray ﬁndings.
Number Percent
Normal 19 38.0
Patchy opacity 12 24.0
Hyper-inﬂation 15 30.0
Bronchiectatic changes 4 8.0
Total 50 100.0
Table 6 Diagnosis of patients.
Number Percent
Community-acquired pneumonia 12 24.0
COPD, AE 34 68.0
Bronchiectasis 4 8.0
Total 50 100.0
Table 7 Antibiotics prescribed on admission.
Number Percent
Broad spectrum penicillins and cephalosporins 16 32.0
Cephalosporins 21 42.0
Cephalosporins and macrolides 3 6.0
Broad spectrum penicillins and
aminoglycosides
6 12.0
Broad spectrum penicillins, aminoglycosides
and metronidazole
2 4.0
Cephalosporins and metronidazole 2 4.0
Total 50 100.0
Table 8 Route of antibiotic administration.
Number Percent
Parenteral 41 82.0
Oral and parenteral 9 18.0
Total 50 100.0
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(68%), fever in 26 patients (52%) and haemoptysis in 10
patients (20%). As regards the clinical signs, sonorous ronchi
were heard in 40 patients (80%), coarse crepitations in 26
patients (52%) and signs of consolidation were found in 12
patients (24%).
Table 5 shows that 19 (38%) of chest X-rays included in the
study were normal, 15 (30%) of them showed hyper-inﬂation,12 (24%) of them showed patchy opacity and 4 (8%) of them
showed bronchiectatic changes.
Table 6 shows that the majority of patients included in the
study had COPD, AE 34 (68%), 12 (24%) had CAP and 4
(8%) of them had bronchiectasis.
Table 7 shows that the majority of patients included in the
study received cephalosporins (42%), combination of broad
spectrum penicillins and cephalosporins (32%), combination
of broad spectrum penicillins and aminoglycosides (12%),
and combination of macrolides and cephalosporins (6%) on
admission.
Table 8 shows that the patients included in the study (82%)
received the AB prescribed on admission via parenteral route,
while only (18%) via oral and parenteral routes.
Table 9 Duration of antibiotic therapy on admission.
Number Percent
5 days 30 60.0
7 days 15 30.0
10 days 5 10.0
Total 50 100.0
Table 10 Change of AB group.
Number Percent
No 49 98.0
Yes 1 2.0
Total 50 100.0
Table 13 Number of patients with LRTIS/week?
Frequency Percent
1–5 1 5.0
6–10 2 10.0
>11 17 85.0
Total 20 100.0
Table 14 Main source of your information about antibiotics
(ABs).
Frequency Percent
Textbooks 8 40.0
Internet 1 5.0
Pharmaceutical companies 6 30.0
Medical journals 1 5.0
Lectures 4 20.0
Total 20 100.0
Table 15 In case you prescribe ABS, this is usually:
Frequency Percent
Empirical 19 95.0
According to culture and sensitivity 1 5.0
Total 20 100.0
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study received the AB prescribed on admission for 5 days
(60%), followed by 7 days (30%) and 10 days (10%).
Table 10 shows that the AB group prescribed on admission
was changed only in (2%) of the patients, while in (98%) of
them, no change was done. This case changed antibiotics to
cephalosporins for (5) days and quinolones for (10) days
because there was no complete clinical improvement and the
appearance of another patch in the chest X-ray.
Doctors
Table 11 shows that (25%) of the physicians included in the
study had master’s degree, (50%) had diploma, (25%) had
M.B., B.Ch.
Table 12 shows that(55%) of the physicians included in the
study had 6–10 years of experience, (25%) of them had
21 years of experience, (10%) of them had 11–15 years of
experience and (10%) of them had <5 years of experience
Do you frequently deal with patients with lower respiratory tract
infections?
All doctors answered with (Yes)Table 11 What is your medical education?
Frequency Percent
M.B., B.Ch 5 25.0
Diploma 10 50.0
Master 5 25.0
Total 20 100.0
Table 12 Years of Experience.
Frequency Percent
<5 years 2 10.0
6–10 years 11 55.0
11–15 years 2 10.0
21 years 5 25.0
Total 20 100.0Table 13 shows that the majority of physicians (85%)
included in the study dealt with more than 11 patients with
LRTIS per week, (10%) of them dealt with 6–11 patients
with LRTIS per week, (5%) of them dealt with 1–5 patients
with LRTIS per week.
Table 14 shows that 40% of the physicians included in the
study depended on text books, 30% of them depended on
pharmaceutical companies, and 20% on lectures, while 5%
depended on the internet and 5% on medical journals as a
main source of information about antibiotics.Table 16 If empirical, it’s according to what?
Frequency Percent
Own experience 14 70.0
International guidelines 4 20.0
National guidelines 2 10.0
Total 20 100.0
Table 17 Route of AB administration is usually according to:
Frequency Percent
Severity of infection 16 80.0
Availability of Abs 2 10.0
Cost of AB 1 5.0
Site of care 1 5.0
Total 20 100.0
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study (95%) used to prescribe AB empirically, while only
5% of them used to prescribe AB according to culture and
sensitivity.
Table 16 shows that own experience as a reference for
empirical AB prescription was 70%, followed by international
guidelines (20%), while the national guidelines was 10%.
Does the presence of co-morbid disease affect your AB
prescription?
All doctors answered with (Yes).
Table 17 shows that the route of AB administration is usu-
ally according to severity of infection (80%), followed by avail-
ability of Abs (10%), then site of care (5%) and cost of AB
(5%).
Table 18 shows that quinolones were the most common
ABs prescribed for empirical therapy (45%), followed by
broad spectrum penicillins (25%), cephalosporins (10%),
broad spectrum penicillins and aminoglycosides (5%), amoxi-
cillin and clavulanic acid (5%), broad spectrum penicillins and
cephalosporins (5%), and quinolones and macrolides (5%).Table 18 What is the most frequently prescribed AB for
empirical therapy for LRTIs?
Frequency Percent
Broad spectrum penicillins 5 25.0
Cephalosporins 2 10.0
Quinolones 9 45.0
Amoxicillin and clavulanic acid 1 5.0
Broad spectrum
penicillins + aminoglycosides
1 5.0
Broad spectrum
penicillins + cephalosporins
1 5.0
Quinolones and macrolides 1 5.0
Total 20 100.0
Table 19 How long is the period of empirical therapy you
give to your patients with LRTIs?
Frequency Percent
4–7 days 10 50.0
7–10 days 10 50.0
Total 20 100.0
Table 20 What is the most frequently modiﬁed AB based on
culture?
Frequency Percent
Cephalosporins 3 15.0
Quinolones 6 30.0
Carbapenems 1 5.0
Missing 10 50.0
Total 20 100.0
Missing system = 10 physicians refusing answering this question.Table 19 shows that 50% of the physicians included in the
study preferred 4–7 days as durations for empirical therapy
and the other 50% preferred 7–10 days.
Regarding the most frequently modiﬁed AB based on cul-
ture, Table 20 shows that Quinolones were 30%, followed by
cephalosporins 15%, and carbapenems at about 5%.
Table 21 shows that quinolones were the most frequently
prescribed ABs for CAP (65%), followed by cephalosporins
(20%), and broad spectrum penicillins (15%).
Table 22 shows that quinolones were the most frequently
prescribed ABs for HAP (40%), followed by cephalosporins
(20%), and aminoglycosides (5%).
Table 23 shows that quinolones were the most frequently
prescribed ABs for COPD, AE (70%), followed by broad spec-
trum penicillins (10%) cephalosporins (10%), tetracyclines
(5%) and amoxicillin and clavulanic acid (5%).
Table 24 shows that the majority of physicians included in
the study (55%) depended on clinical and radiological ﬁndings
for AB prescription, 25% depended on clinical, radiological
ﬁndings and laboratory data, 15% depended on clinical condi-
tion only, and 5% depended on radiological ﬁndings only.
Regarding the most important symptom when AB prescrip-
tion was based on clinical assessment, purulence of sputum
represented 55%, fever represented 30%, while progression
of dyspnea represented 15% (see Table 25).Table 21 What is the most frequently prescribed AB for
CAP?
Frequency Percent
Broad spectrum penicillins 3 15.0
Cephalosporins 4 20.0
Quinolones 13 65.0
Total 20 100.0
Table 22 What is the most frequently prescribed AB for
HAP?
Frequency Percent
Aminoglycosides 1 5.0
Cephalosporins 4 20.0
Quinolones 8 40.0
Missing 7 35.0
Total 20 100.0
Missing system = 7 physicians (35%) refusing answering this
question
Table 23 What is the most frequently prescribed AB for
COPD?
Frequency Percent
Broad spectrum penicillins 2 10.0
Cephalosporins 2 10.0
Quinolones 14 70.0
Tetracyclines 1 5.0
Other(amoxicillin and clavulanic acid) 1 5.0
Total 20 100.0
Table 24 Decision of AB prescription is usually based on:
Frequency Percent
Clinical condition 3 15.0
Radiological data 1 5.0
Clinical condition + radiological data 11 55.0
Clinical condition + laboratory
data + radiological data
5 25.0
Total 20 100.0
Table 25 If the decision of AB prescription is based on
clinical assessment, the most important symptom is:
Frequency Percent
Fever 6 30.0
Progression of dyspnea 3 15.0
Purulence of sputum 11 55.0
Total 20 100.0
Table 26 If the decision of AB prescription is based on lab
data, the most important is:
Frequency Percent
Leucocytosis 1 5.0
ESR 2 10.0
Sputum gram stain 4 20.0
Sputum C&S 13 65.0
Total 20 100.0
Table 27 How do you usually judge the efﬁcacy of AB
prescribed?
Frequency Percent
Improvement of general condition 13 65.0
Decrease of white blood count 1 5.0
Change of sputum character 6 30.0
Total 20 100.0
Table 28 Duration after which you decide that the prescribed
AB is ineffective:
Frequency Percent
2–3 days 8 40.0
3–5 days 6 30.0
>5 days 6 30.0
Total 20 100.0
Table 29 In case you judge that prescribed AB is ineffective
you usually:
Frequency Percent
Change AB group 10 50.0
Order C&S examination of sputum 6 30.0
Revise the diagnosis 4 20.0
Total 20 100.0
Table 30 Do you usually make sure that the AB prescribed is
that the one actually given to the patient?
Frequency Percent
Yes 17 85.0
No 3 15.0
Total 20 100.0
Table 31 Do you ask the patient about AB history in the last
3 months?
Frequency Percent
Yes 15 75.0
No 5 25.0
Total 20 100.0
Table 32 Does the patient sometimes inﬂuence your AB
prescription decision?
Frequency Percent
Yes 10 50.0
No 10 50.0
Total 20 100.0
150 M.M. Ahmed et al.Regarding the most important laboratory ﬁnding if AB pre-
scription was based on laboratory data, sputum culture and
sensitivity represented 65%, sputum gram stain 20%, and
ESR 10%, while leucocytosis represented 5% (see Table 26).
Table 27 shows that 65% of the physicians included in the
study considered improvement of general condition as the
most important factor in determining the efﬁcacy of AB
prescribed, 30% considered change of sputum character, while
5% considered decrease of white blood cells count.
Table 28 shows that 40% of the physicians included in the
study decided that the prescribed AB was ineffective after
2–3 day duration, 30% after 3–5 day duration, while 30% after
more than 5 day duration.
50% of the physicians included in the study changed the
AB group, 30% ordered sputum culture and sensitivity and
20% revised the diagnosis in case the prescribed AB was
ineffective (see Table 29).
The majority of the physicians included in the study 85%
used to make sure that the prescribed AB was the one actually
given to the patient, while 15% of them did not (see Table 30).
75% of the physicians included in the study used to ask the
patient about AB history in the last 3 months, while 25% of
them did not (see Table 31).
As regards 50% of the physicians included in the study,
their AB prescription decision might be sometimes affected
by the patient and for the other 50%, their AB prescription
decision was not affected (see Table 32).
Table 33 Do you ask the patient before prescribing the AB if
he is sensitive to certain AB?
Frequency Percent
Yes 16 80.0
No 4 20.0
Total 20 100.0
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ask the patient before prescribing the AB if he was sensitive to
a certain AB, while 20% did not (see Table 33).
Discussion
Most people will develop an acute respiratory tract infection
(RTI) every year. RTIs are also the commonest acute problem
dealt with in primary care – the ‘bread and butter’ of daily
practice. Management of acute RTIs in the past concentrated
on advising prompt antibiotic treatment of presumptive bacte-
rial infections. This advice was appropriate, in an era of high
rates of serious suppurative and non-suppurative complica-
tions, up to and including the immediate post-war period.
However, in modern developed countries, rates of major com-
plications are now low. In addition, there is no convincing evi-
dence, either from international comparisons or from evidence
within countries, that lower rates of prescribing are associated
with higher rates of complications. Therefore, much of the his-
torically high volume of prescribing to prevent complications
may be inappropriate. After a fall in antibiotic use in the late
1990s, antibiotic prescribing in the UK has now reached a pla-
teau and the rate is still considerably higher than the rates of
prescribing in other northern European countries. Most people
presenting in primary care with an acute uncomplicated RTI
will still receive an antibiotic prescription – with many doctors
and patients believing that this is the right thing to do. There
may be several problems with this. First, complications are
now much less common, so the evidence for symptomatic ben-
eﬁt should be strong to justify prescribing; otherwise many
patients may have unnecessary antibiotics, needlessly exposing
them to side effects. Second, except in cases where the antibi-
otic is clinically necessary, patients, and their families and
friends, may get the message from healthcare professionals
that antibiotics are helpful for most infections. This is because
patients will understandably attribute their symptom resolu-
tion to antibiotics, and thus maintain a cycle of ‘medicalizing’
self-limiting illness. Third, international comparisons make it
clear that antibiotic resistance rates are strongly related to
antibiotic use in primary care. This is potentially a major pub-
lic health problem both for our own and for future genera-
tions; unless there is clear evidence of beneﬁt, we need to
maintain the efﬁcacy of antibiotics by more judicious antibi-
otic prescribing [9].
The aim of this study was to evaluate the prescription prac-
tices of antibiotics in lower respiratory tract infections at
Sohag Chest Hospital. The study had questionnaires that
included antibiotics prescription pattern among physicians
who were responsible for prescribing antibiotics for patients
with lower respiratory tract infections. Twenty physicians were
included in this study.In the present study, 40% of physicians included depended
on text books as their main source of information and 30% of
them depended on pharmaceutical companies as their main
source of information. These results match with the study done
by Vancelik et al. [10], who found that the most frequent
resources used in the case of any problems in prescribing pro-
cess were drug guides of pharmaceutical companies (73.7%),
medical books (48.7%) and the documents of pharmaceutical
companies other than drug guides (33.6%). Also, the results
match with those of the study done by McGettigan et al.
[11], who performed their study upon 200 general practitioners
and 230 hospital doctors. They stated that pharmaceutical
companies, therapeutics bulletin and medical journals were
the main sources of information about antibiotics. On the
other hand, the results match with those of the study done
by Khaliq et al. [12], who performed their study upon 304 doc-
tors. They stated that the source of medical information, which
is used most commonly, is medical books. This was afﬁrmed
by 185 (71.4%) doctors. 131 (50.6%) doctors answered in pos-
itive about reading electronic journals to keep themselves
updated. A cross-sectional, exploratory survey was performed
among 152 GPs working in the primary health centers and
hospitals in the Erzurum province of Eastern Turkey in
2006. The study done by Abbas et al. [8] showed that text
books were the main source of information about antibiotics
for the physicians included in the study.
In the present study, 60% of the physicians included
depended on their own experience. These results matched with
the study done by Bugnon-Reber et al. [13], who found that
AB misuse was 47% with improper implantation of interna-
tional guidelines, but the study done by Giammarino et al.
[14], performed one year after the introduction of local guide-
lines, demonstrated a generally good adherence to local AB
guidelines (71%). Similarly, Lutters et al. [15] showed in an
interventional cohort study that, after an intensive intervention
period consisting of physicians’ educational program, the
guidelines were correctly implemented in 75% of surveyed
patients. Also, the study done by Mazzaglia et al. [16] showed
that a survey was carried out, in order to describe the prescrip-
tive behavior among Sicilian general practitioners (GPs) in
choosing an empirical antibiotic regimen for LRTIs in adult
patients and began an educational process which involved
the same GPs in decisions regarding their prescriptions and
in performing local guidelines. The results of the present study
did not match with those of the study done by Abbas et al. [8],
where 62% of the physicians included in the study depended
on the international guidelines as a reference for empirical
AB prescription. This difference might be due to the fact that
the study done by Abbas et al. [8] was performed on 100 physi-
cians, ﬁfty-seven of them were from Chest Department and the
other 43 were from Internal Medicine Department and worked
at Ain Shams University Hospital.
In the present study, all physicians included took into con-
sideration the presence of co-morbid diseases during AB pre-
scription. This result matched with IDSA/ATS Guidelines,
[17] that stated that the presence of co-morbid diseases should
inﬂuence the choice of AB group. Also, this result matched
with the study done by Abbas et al. [8], who found that
(97%) of physicians took into consideration the presence of
co-morbid diseases during AB prescription.
In the current study, the most frequently prescribed ABS
for empirical therapy were quinolones (45%) followed by
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This result did not match with that of the study done by
Mazzaglia et al. [16], who found that the most frequently used
antibacterial agents were cephalosporins (55.0%), penicillins
(11.7%), ﬂuoroquinolones (11. 4%), and macrolides (10.1%)
and combinations of penicillins with beta-lactamase inhibitors
(7.9%), together, represented 41.1% of the remaining antibi-
otic prescriptions. Also, there is a mismatch with the results
of the study done by Giammarino et al. [14], who stated that
the most frequently prescribed ABs for empirical therapy were
amoxicillin/clavulanic acid (51%), followed by cefepime
(43%), ciproﬂoxacin (30%) and clarithromycin (17%). This
difference with the previously mentioned studies might be
due to the fact that they depended on local guidelines rather
than the current study. Again, the results of the present study
did not match with those of the study done by Abbas et al. [8]
that showed that broad spectrum penicillins (33%), followed
by cephalosporins (17%) were the most frequently prescribed
ABs for empirical therapy. This difference might be due to
the fact that the study done by Abbas et al. [8] included 100
physicians; double the number enrolled in the present study
and the fact that ﬁfty-seven of them were from the Chest
Department, and the other 43 were from the Internal
Medicine Department.
In the current study, 50% of the physicians included pre-
ferred 4–7 days as duration for empirical therapy and 50%
preferred 7–10 days. This matched with IDSA/ATS
Guidelines, [17] that mentioned that the duration of empirical
antibiotics therapy should be a minimum of 5 days and the
patient should be afebrile for 48–72 h. Also, the results of
the study done by Abbas et al. [8] revealed that 55% of the
physicians preferred 4–7 days as the duration for empirical
therapy.
In the current study, the most frequently prescribed ABS
for CAP was quinolones (65%), followed by cephalosporin
(20%) and broad spectrum penicillin (15%). This matched
with IDSA/ATS Guidelines, [17] that stated that respiratory
ﬂuoroquinolones are indicated as the ﬁrst choice for outpatient
treatment with the presence of co-morbidities and inpatient
non ICU. Macrolides are indicated as the ﬁrst choice for out-
patient treatment without risk factors and previously healthy
but a combination of Ab lactam (as ceftrixone) plus either ﬂu-
oroquinolones or azithromycin is the ﬁrst choice for inpatient,
ICU treatment. The study done by Abbas et al. [8] found that
the most frequently prescribed ABs for CAP were broad spec-
trum penicillins (32%), followed by macrolides (18%). The dif-
ference between that study and the present study could be due
to the fact that the study done by Abbas et al. [8] included 100
physicians, ﬁfty-seven of them were from Chest Department,
and the other 43 were from Internal Medicine Department.
In the current study, the most frequently prescribed ABs for
HAP were quinolones (40%), followed by cephalosporins
(20%) and aminoglycosides (5%). This matched with ATS
Guidelines for HAP, VAP and HCAP [18], where quinolones
(levoﬂoxacin, moxiﬂoxacin, or ciproﬂoxacin) or cephalospor-
ins (ceftriaxone) are indicated for initial empirical antibiotic
therapy for hospital-acquired pneumonia or ventilator-
associated pneumonia in patients with no known risk factors
for multidrug-resistant pathogens, early onset and disease
severity. Also, antipseudomonal ﬂuoroquinolones (ciproﬂoxa-
cin or levoﬂoxacin) or aminoglycosides (amikacin, gentamicin,
or tobramycin) plus anti pseudomonal cephalosporin(cefepime, ceftazidime) or anti pseudomonal carbapenem (imi-
penem or meropenem) or (b-lactam/b-lactamase inhibitor (pi
peracillin–tazobactam) plus linezolid or vancomycin are indi-
cated for the initial empirical antibiotic therapy for hospital-
acquired pneumonia, ventilator-associated pneumonia and
healthcare-associated pneumonia in patients with late-onset
of disease, risk factors for multidrug-resistant pathogens and
all disease severity. The study done by Abbas et al. [8] found
that the most frequently prescribed ABs for HAP were quino-
lones (21%), followed by cephalosporins (16%).
In the current study, the most frequently prescribed ABs for
COPD, AE were quinolones (70%), followed by broad spec-
trum penicillin (10%), cephalosporins (10%), tetracycli-
nes(5%) and amoxicillin and clavulanic acid (5%). This
result generally agrees with that of the study done by
Siempos et al. [19], who stated that the treatment success in
microbiologically evaluable patients was lower for macrolides
compared with quinolones. Fewer quinolone-recipients experi-
enced a recurrence of ABECB after resolution of the initial epi-
sode compared with macrolide-recipients during the 26-week
period following therapy. Adverse effects in general were sim-
ilar between macrolides and quinolones. Administration of
A/C was associated with more adverse effects (mainly diar-
rhea) than quinolones. Macrolides, quinolones and amoxi-
cillin/clavulanate may be considered equivalent for the
treatment of patients with an acute bacterial exacerbation of
chronic bronchitis in terms of short-term effectiveness.
Quinolones are associated with better microbiological success
and fewer recurrences of acute bacterial exacerbation of
chronic bronchitis than macrolides, while amoxicillin/clavu-
lanate is associated with more adverse effects than both com-
parators. Another match of this result is encountered with
that of the study done by Dimopoulos et al. [20], who stated
that, the ﬁrst-line antibiotics (i.e., amoxicillin, ampicillin,
pivampicillin trimethoprim/sulfamethoxazole, and doxycy-
cline) were associated with a lower treatment success compared
to second-line antibiotics (i.e., amoxicillin/clavulanic acid,
macrolides, second-generation or third-generation cephalos-
porins, and quinolones) in the clinically evaluable patients.
There were no differences among the compared regimens
regarding mortality or treatment success in microbiologically
evaluable patients, or adverse effects in general or diarrhea
in particular. Compared to ﬁrst-line antibiotics, second-line
antibiotics are more effective, but not less safe, when adminis-
tered to patients with AECB. The available data did not allow
for stratiﬁed analyses according to the presence of risk factors
for poor outcome, such as increased age, impaired lung func-
tion, airway obstruction, and frequency of exacerbations; this
fact should be taken into consideration when interpreting the
ﬁndings of this meta-analysis. The study done by Abbas
et al. [8] found that, the most frequently prescribed ABs for
COPD, AE were broad spectrum penicillins (39%), followed
by cephalosporins (24%). This difference might be due to the
fact that this study was performed on 100 physicians, ﬁfty-
seven of them were from the Chest Department and the other
43 were from the Internal Medicine Department.
The majority of physicians included in the study (85%)
used to make sure that the AB prescribed is that the one actu-
ally given to the patient. As failure of the treatment might be
due to the fact that some patients might receive another AB
group, sub therapeutic dose or another route of administra-
tion. This matched with the study done by Abbas et al. [8] that
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that the prescribed AB was the one actually given to the
patient.
In the current study, 55% of the physicians depended on
clinical and radiological ﬁndings for AB prescription, 25%
of them depended on clinical, radiological and laboratory
data, 15% of them depended on clinical condition and 5%
of them depended on radiological ﬁndings only. The results
did not match the study done by Abbas et al. [8] that showed
that 61% of the physicians depended on clinical, laboratory
and radiological ﬁndings for AB prescription. The difference
could be due to the study which included larger number of
physicians (100), 57 of them were from the Chest
Department and the other 43 were from the Internal
Medicine Department.
55% of the physicians included in the study decided that the
most important symptom when AB prescription was based on
clinical assessment is purulence of sputum. This matched with
Coenen et al. [21], who stated that the patients presenting with
acute cough in primary care who have discolored sputum are
more likely to be prescribed antibiotics than those not produc-
ing sputum or producing white sputum. This conﬁrms previous
ﬁndings that physicians are more likely to prescribe antibiotics
to patients with presumed respiratory tract infections (RTIs)
who produce purulent sputum. They analyzed data from 72
Flemish general practitioners (GPs) on the management of
1448 patients with acute cough. The presence of sputum was
associated with an increased risk of antibiotic prescription
independent of patient and clinician characteristics. The study
done by Fischer et al. [22] directly observed 30 GPs in
Germany managing 237 patients with RTIs. Purulent sputum
was associated with an increased chance of antibiotic prescrip-
tion. The study done by Abbas et al. [8] found that the most
important symptom when AB prescription was based on
clinical assessment was purulence of sputum (59%).
In the current study, the most important laboratory ﬁnding
if AB prescription was based on laboratory data was sputum
culture and sensitivity represented 65%, sputum gram stain
20%, and ESR 10% while leucocytosis represented 5%. This
matched with the study done by Abbas et al. [8] that showed
the most important laboratory ﬁnding if AB prescription was
based on laboratory data was sputum culture and sensitivity
represented 47%.
In the current study, improvement of general condition was
the most important factor in determining the efﬁcacy of AB
prescribed (65%) followed by change of sputum character
(30%) and white blood cell count (5%). The results matched
with the study done by Abbas et al. [8] that stated that 45%
of the physicians considered improvement of general condition
as the most important factor in determining the efﬁcacy of AB
prescribed.
40% of the physicians included in that study decided that
the prescribed AB was ineffective after 2–3 day duration and
(30%) after 3–5 day duration. This matched with IDSA/ATS
Guidelines, [17] recommendations, that mentioned that no
response can be deﬁned as absence of or delay in achieving
clinical stability (Temperature 6 37.8 C, Heart rate 6 100
beats/min, Respiratory rate 6 24 breaths/min, Systolic blood
pressureP 90 mmHg, Arterial oxygen saturationP 90% or
pO2P 60 mmHg on room air, ability to maintain oral intake
and normal mental status). When these criteria were used, the
median time to achieve clinical stability was 3 days for allpatients. Deterioration and development of respiratory failure
or hypotension > 72 h after initial treatment is often related to
intercurrent complications, deterioration in underlying disease,
or development of nosocomial super infection. The results also
matched with the study done by Abbas et al. [8], who decided
that 57% of the physicians included in the study showed that
the prescribed AB was ineffective after 2–3 day duration, 33%
after 3–5 day duration.
50% of the physicians included in the study changed the
AB group in case the prescribed AB was ineffective, 30% of
them ordered sputum culture and sensitivity and 20% of them
revised the diagnosis. The results did not match with the study
done by Abbas et al. [8], that showed that 59 of the physicians
included in the study (59%) ordered sputum culture and sensi-
tivity in case the prescribed AB was ineffective, 28 changed the
AB group, 11 revised the diagnosis, while 2 changed the AB
dose. That difference might be due to the fact that the study
done by Abbas et al. [8] included 100 physicians, ﬁfty-seven
of them from the Chest Department and the other 43 from
the Internal Medicine Department, working at Ain Shams
University Hospital and depended on international guidelines.
The majority of the physicians included in the study (75%)
used to ask the patient about the AB history in the last
3 months. This matched with IDSA/ATS Guidelines, [17] rec-
ommendations, as recent AB taking in the last 3 months
should inﬂuence the choice of AB group. In such a case, an
alternative from a different class should be selected. Also,
recent AB therapy increases the likelihood of infection with
drug-resistant streptococcal pneumonia. This result matches
also with the study done by Abbas et al. [8], who showed that
73% of the physicians used to ask the patients about the AB
history in the last 3 months.
Most of the physicians included in the study (80%) used to
ask the patient before prescribing the AB if he was sensitive to
a certain AB. In 50% of the physicians, their AB prescription
decision might be sometimes affected by the patient. These two
factors are very important. They might contribute to the fail-
ure of AB prescription practice, besides decreasing the possi-
bility of unnecessary complications. The results match with
those of the study done by Abbas et al. [8], who showed that
81% of physicians used to ask the patient before prescribing
the AB if he was sensitive to certain AB.
In the current study, 50 patients were included, 68% of the
patients admitted at Sohag Chest Hospital with COPD, AE
followed by 24% of the patients admitted with CAP and 8%
with bronchiectasis. This matched with a study done by
Murray et al. [23] that included 281 patients (121 exacerbations
of COPD, 94 pneumonias, 24 exacerbations of asthma and 42
LRTI/bronchitis or other chest infections).
In the current study, LRTIS were more prevalent in males
(64%) than in females (36%). This matched with a study done
by Kelsey et al. [24], who showed that the prevalence was
greater in males than in females.
Cephalosporins (42%) followed by a combination of broad
spectrum penicillins and cephalosporins (32%), a combination
of broad spectrum penicillins and aminoglycosides (12%) fol-
lowed by a combination of macrolides and cephalosporins
(6%) were prescribed on admission for the patients included
in the study in comparison to a similar survey study performed
by Mazzaglia et al. [16], who stated that the most frequently
used antibacterial agents were cephalosporins (55.0%) and
penicillins (11.7%). The results did not match with the study
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penicillins (24%) and combination of macrolides and cepha-
losporins (24%) were prescribed on admission for the patients.
This difference could be due to the fact that Abbas et al’ study
included 50 patients, 25 patients were admitted at the RICU
and the other 25 patients were admitted at the ward.
In the current study, the duration of AB prescribed on
admission was 5 days’ duration (60%) and seven days’ dura-
tion (30%). These results were consistent with the previous
results obtained by the questionnaire of physicians included
in the study regarding the duration of the empirical therapy.
These results also matched with the recommendations of dif-
ferent international guidelines as IDSA/ATS Guidelines, [17],
where 5 days’ duration appears to be the minimal overall dura-
tion of the empirical therapy documented to be effective. Still,
few exceptions exist as in the case of the presence of extra pul-
monary infection, such as meningitis or endocarditis. Putting
in mind that some antibiotics (such as azithromycin) are
administered for a short time yet they have a long half-life at
respiratory sites of infection. Also, a similar study was done
by Dunbar et al. [25], who stated that a high-dose (750 mg)
levoﬂoxacin therapy for 5 days was equally successful and
resulted in more afebrile patients by day 3 than did the 500-
mg dose for 7–10 days. Also, Rizzato et al. [26] stated that;
in trials of antibiotic therapy for CAP. Azithromycin has been
used for 3–5 days as oral therapy for outpatients, with some
reports of single-dose therapy for patients with atypical patho-
gen infections. This also matched with the study done by
Abbas et al. [8], who showed that the duration of AB pre-
scribed on admission was 5 days (38%) and seven days (34%).
In the current study, almost all of the patients included in
the study (82%) received the AB prescribed on admission via
parenteral route, while (18%) via oral and parenteral routes.
A similar survey study performed by Giammarino et al. [14]
among 129 patients at Swiss hospital found that 63% of admit-
ted patients received parenteral therapy as initial AB treat-
ment. This also matched with the study done by Abbas et al.
[8] who showed that 98% of patients received the AB
prescribed on admission via parenteral route.Conclusions
1. AB prescription practices need to be well evaluated in order
to formulate an acceptable rationale aiming at improving
the global situation of antibiotic use.
2. Many points have to be taken into consideration like
increasing awareness of physicians about different widely
accepted guidelines.
3. Other items, including patient compliance, patient demand,
ﬁnancial causes, pharmaceutical companies, pressure and
drug therapy use monitoring, should be put into considera-
tion when prescribing antibiotics.
Recommendations
1. There is an increasing need to improve accessibility to the
widely accepted guidelines.
2. There is an increasing need for regular, updated and revised
local guidelines.3. Supporting the physician decision making, improving
patients’ compliance, control excessive patient demand
and applying of monitoring of drug therapy use, may
improve AB prescription practice.
4. Further studies on a larger scale to identify the contributing
factors of the AB prescription practice problems are
needed.
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